Delphinus Medical Technologies has raised $8.2 million in a new mixed-shelf offering, according to an SEC filing posted this week.
The Novi, Mich.-based company is looking for an additional $16.8 million in the round, for a total of $25 million, and has not yet said how it plans to spend funds raised in the round.
Delphinus produces the SoftVue whole breast ultrasound system. The device uses a unique, circular ultrasound transducer to create cross-sectional ultrasound slices of the entire volume of breast tissue and distinguish potential tumors in dense breast tissue.
Money in the round came from 9 unnamed investors, according to the SEC filing, with the 1st sale recorded on April 13.
In December 2015, Delphinus raised $39.5 million in a Series C round led by Venture Investors for its SoftVue system.
Proceeds from the round, which was joined by new investors Hopen Life Science Ventures and Waycross Ventures and existing backers Arboretum Ventures, Beringea, and North Coast Technology Investors, supported regulatory and commercialization expenses for the SoftVue.